Related Experiment Video
Updated: Dec 3, 2025
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
19.5K
Pediatric laryngeal sarcoma: Systematic review and pooled analysis.
Taha A Mur1, William R Pellegrini2, Zaroug Jaleel2
1Department of Otolaryngology-Head and Neck Surgery, Boston University Medical Center, Boston, MA, USA.
International Journal of Pediatric Otorhinolaryngology
|October 29, 2020
Summary
Pediatric laryngeal sarcoma is rare, with rhabdomyosarcoma being most common. Patient and tumor factors did not impact survival in this review of pediatric soft tissue sarcoma cases.
Area of Science:
- Pediatric oncology
- Laryngeal diseases
- Mesenchymal tumors
Background:
- Sarcomas are rare, diverse tumors of mesenchymal origin affecting all ages.
- Disease site influences survival in sarcoma patients.
- Limited research exists on pediatric laryngeal sarcoma treatment.
Purpose of the Study:
- To analyze existing literature on pediatric laryngeal sarcoma.
- To identify patient and tumor characteristics impacting outcomes.
Main Methods:
- A structured literature review following PRISMA guidelines was conducted.
- Case reports of pediatric (age ≤17) laryngeal sarcoma were identified.
- Data from 37 patients across 29 case reports were analyzed.
Main Results:
- Rhabdomyosarcoma (69.4%) and synovial sarcoma (19.4%) were the most common subtypes.
- The supraglottis was the most frequent tumor subsite (62.1%).
- Survival was not significantly impacted by tumor site, treatment, histology, or gender.
Conclusions:
- Soft tissue sarcoma is uncommon in the pediatric larynx.
- Patient and tumor characteristics did not demonstrate an impact on outcomes.
- High-quality case report documentation is crucial for advancing understanding.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
151
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
151
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
101
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
101
01:03Rous Sarcoma Virus (RSV) and Cancer
5.8K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.8K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
124
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
124